X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA GLENMARK PHARMA NATCO PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 23.2 12.0 193.3% View Chart
P/BV x 17.6 3.2 554.3% View Chart
Dividend Yield % 0.7 0.4 171.0%  

Financials

 NATCO PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
GLENMARK PHARMA
Mar-17
NATCO PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs877993 88.3%   
Low Rs424729 58.1%   
Sales per share (Unadj.) Rs223.4325.5 68.6%  
Earnings per share (Unadj.) Rs31.139.3 79.1%  
Cash flow per share (Unadj.) Rs40.348.7 82.8%  
Dividends per share (Unadj.) Rs5.002.00 250.0%  
Dividend yield (eoy) %0.80.2 331.1%  
Book value per share (Unadj.) Rs219.5159.2 137.9%  
Shares outstanding (eoy) m33.07282.17 11.7%   
Bonus/Rights/Conversions PAESOP-  
Price / Sales ratio x2.92.6 110.0%   
Avg P/E ratio x20.921.9 95.5%  
P/CF ratio (eoy) x16.117.7 91.2%  
Price / Book Value ratio x3.05.4 54.8%  
Dividend payout %16.15.1 316.2%   
Avg Mkt Cap Rs m21,504242,991 8.8%   
No. of employees `000NA13.0 0.0%   
Total wages/salary Rs m1,12816,408 6.9%   
Avg. sales/employee Rs ThNM7,083.9-  
Avg. wages/employee Rs ThNM1,265.4-  
Avg. net profit/employee Rs ThNM855.1-  
INCOME DATA
Net Sales Rs m7,38991,857 8.0%  
Other income Rs m167374 44.7%   
Total revenues Rs m7,55692,230 8.2%   
Gross profit Rs m1,79320,367 8.8%  
Depreciation Rs m3042,644 11.5%   
Interest Rs m3662,373 15.4%   
Profit before tax Rs m1,29015,724 8.2%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m3093,827 8.1%   
Profit after tax Rs m1,02711,088 9.3%  
Gross profit margin %24.322.2 109.5%  
Effective tax rate %23.924.3 98.3%   
Net profit margin %13.912.1 115.2%  
BALANCE SHEET DATA
Current assets Rs m3,68168,746 5.4%   
Current liabilities Rs m3,12327,027 11.6%   
Net working cap to sales %7.645.4 16.6%  
Current ratio x1.22.5 46.3%  
Inventory Days Days8985 105.3%  
Debtors Days Days5996 61.4%  
Net fixed assets Rs m7,68524,132 31.8%   
Share capital Rs m331282 117.2%   
"Free" reserves Rs m6,67044,643 14.9%   
Net worth Rs m7,25944,925 16.2%   
Long term debt Rs m95545,363 2.1%   
Total assets Rs m11,957117,639 10.2%  
Interest coverage x4.57.6 59.3%   
Debt to equity ratio x0.11.0 13.0%  
Sales to assets ratio x0.60.8 79.1%   
Return on assets %11.711.4 101.9%  
Return on equity %14.224.7 57.3%  
Return on capital %20.719.1 108.2%  
Exports to sales %39.40-   
Imports to sales %5.70-   
Exports (fob) Rs m2,908NA-   
Imports (cif) Rs m421NA-   
Fx inflow Rs m3,44556,152 6.1%   
Fx outflow Rs m7038,084 8.7%   
Net fx Rs m2,74348,068 5.7%   
CASH FLOW
From Operations Rs m1,4406,574 21.9%  
From Investments Rs m-1,089-7,124 15.3%  
From Financial Activity Rs m-3535,432 -6.5%  
Net Cashflow Rs m-11,992 -0.1%  

Share Holding

Indian Promoters % 52.0 48.3 107.7%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 6.9 113.6%  
FIIs % 16.6 34.4 48.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 10.5 247.6%  
Shareholders   25,395 56,727 44.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   DIVIS LABORATORIES  WOCKHARDT LTD.  SUN PHARMA  FRESENIUS KABI ONCO.  TTK HEALTHCARE  

Compare NATCO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Rising Dollar after Fed Minutes; F&O Expiry and Top Stocks in Action Today(Pre-Open)

Indian share markets ended largely flat on Thursday following the expiry of derivative contracts for February series. The S&P BSE Sensex ended down by 25 points.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Feb 22, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 5-YR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS